• Home
  • A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.

A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.

Author List
David Yoonsuk Oh, Deepak Kilari, Christopher Darr, Kevin Kayvan Zarrabi, Jessica E. Hawley, Russell Kent Pachynski, Scott T. Tagawa, Yuanquan Yang, Simon Buetikofer, Qing Xia, Gunhild Von Amsberg
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/593758851
Publication Year
2025
Publication Title
David Yoonsuk Oh, Deepak Kilari, Christopher Darr, Kevin Kayvan Zarrabi, Jessica E. Hawley, Russell Kent Pachynski, Scott T. Tagawa, Yuanquan Yang, Simon Buetikofer, Qing Xia, Gunhild Von Amsberg. A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting. Journal of Clinical Oncology. 2025 Feb 10; 43(5_suppl).